The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Remicade (infliximab) Drug Market Research Report 2024
Synopsis
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Remicade (infliximab) Drug market was valued at US$ 2550 million in 2023 and is anticipated to reach US$ 3855 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Remicade (infliximab) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (infliximab) Drug.
Report Scope
The Remicade (infliximab) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Remicade (infliximab) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Remicade (infliximab) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
J & J
Pfizer
Celltrion Healthcare
Epirus Biopharmaceuticals
Samsung Bioepsis
Segment by Type
Brands Drugs
Generic Drugs
Segment by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Pediatric Ulcerative Colitis
Other
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Remicade (infliximab) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Remicade (infliximab) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Remicade (infliximab) Drug market was valued at US$ 2550 million in 2023 and is anticipated to reach US$ 3855 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Remicade (infliximab) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (infliximab) Drug.
Report Scope
The Remicade (infliximab) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Remicade (infliximab) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Remicade (infliximab) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
J & J
Pfizer
Celltrion Healthcare
Epirus Biopharmaceuticals
Samsung Bioepsis
Segment by Type
Brands Drugs
Generic Drugs
Segment by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Pediatric Ulcerative Colitis
Other
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Remicade (infliximab) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Remicade (infliximab) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Remicade (infliximab) Drug Market Overview
1.1 Product Overview and Scope of Remicade (infliximab) Drug
1.2 Remicade (infliximab) Drug Segment by Type
1.2.1 Global Remicade (infliximab) Drug Market Value Comparison by Type (2024-2030)
1.2.2 Brands Drugs
1.2.3 Generic Drugs
1.3 Remicade (infliximab) Drug Segment by Application
1.3.1 Global Remicade (infliximab) Drug Market Value by Application: (2024-2030)
1.3.2 Crohn's Disease
1.3.3 Pediatric Crohn's Disease
1.3.4 Ulcerative Colitis
1.3.5 Pediatric Ulcerative Colitis
1.3.6 Other
1.4 Global Remicade (infliximab) Drug Market Size Estimates and Forecasts
1.4.1 Global Remicade (infliximab) Drug Revenue 2019-2030
1.4.2 Global Remicade (infliximab) Drug Sales 2019-2030
1.4.3 Global Remicade (infliximab) Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Remicade (infliximab) Drug Market Competition by Manufacturers
2.1 Global Remicade (infliximab) Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Remicade (infliximab) Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Remicade (infliximab) Drug Average Price by Manufacturers (2019-2024)
2.4 Global Remicade (infliximab) Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Remicade (infliximab) Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Remicade (infliximab) Drug, Product Type & Application
2.7 Remicade (infliximab) Drug Market Competitive Situation and Trends
2.7.1 Remicade (infliximab) Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Remicade (infliximab) Drug Players Market Share by Revenue
2.7.3 Global Remicade (infliximab) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Remicade (infliximab) Drug Retrospective Market Scenario by Region
3.1 Global Remicade (infliximab) Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Remicade (infliximab) Drug Global Remicade (infliximab) Drug Sales by Region: 2019-2030
3.2.1 Global Remicade (infliximab) Drug Sales by Region: 2019-2024
3.2.2 Global Remicade (infliximab) Drug Sales by Region: 2025-2030
3.3 Global Remicade (infliximab) Drug Global Remicade (infliximab) Drug Revenue by Region: 2019-2030
3.3.1 Global Remicade (infliximab) Drug Revenue by Region: 2019-2024
3.3.2 Global Remicade (infliximab) Drug Revenue by Region: 2025-2030
3.4 North America Remicade (infliximab) Drug Market Facts & Figures by Country
3.4.1 North America Remicade (infliximab) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Remicade (infliximab) Drug Sales by Country (2019-2030)
3.4.3 North America Remicade (infliximab) Drug Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Remicade (infliximab) Drug Market Facts & Figures by Country
3.5.1 Europe Remicade (infliximab) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Remicade (infliximab) Drug Sales by Country (2019-2030)
3.5.3 Europe Remicade (infliximab) Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Remicade (infliximab) Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Remicade (infliximab) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Remicade (infliximab) Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Remicade (infliximab) Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Remicade (infliximab) Drug Market Facts & Figures by Country
3.7.1 Latin America Remicade (infliximab) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Remicade (infliximab) Drug Sales by Country (2019-2030)
3.7.3 Latin America Remicade (infliximab) Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Remicade (infliximab) Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Remicade (infliximab) Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Remicade (infliximab) Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Remicade (infliximab) Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Remicade (infliximab) Drug Sales by Type (2019-2030)
4.1.1 Global Remicade (infliximab) Drug Sales by Type (2019-2024)
4.1.2 Global Remicade (infliximab) Drug Sales by Type (2025-2030)
4.1.3 Global Remicade (infliximab) Drug Sales Market Share by Type (2019-2030)
4.2 Global Remicade (infliximab) Drug Revenue by Type (2019-2030)
4.2.1 Global Remicade (infliximab) Drug Revenue by Type (2019-2024)
4.2.2 Global Remicade (infliximab) Drug Revenue by Type (2025-2030)
4.2.3 Global Remicade (infliximab) Drug Revenue Market Share by Type (2019-2030)
4.3 Global Remicade (infliximab) Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Remicade (infliximab) Drug Sales by Application (2019-2030)
5.1.1 Global Remicade (infliximab) Drug Sales by Application (2019-2024)
5.1.2 Global Remicade (infliximab) Drug Sales by Application (2025-2030)
5.1.3 Global Remicade (infliximab) Drug Sales Market Share by Application (2019-2030)
5.2 Global Remicade (infliximab) Drug Revenue by Application (2019-2030)
5.2.1 Global Remicade (infliximab) Drug Revenue by Application (2019-2024)
5.2.2 Global Remicade (infliximab) Drug Revenue by Application (2025-2030)
5.2.3 Global Remicade (infliximab) Drug Revenue Market Share by Application (2019-2030)
5.3 Global Remicade (infliximab) Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 J & J
6.1.1 J & J Corporation Information
6.1.2 J & J Description and Business Overview
6.1.3 J & J Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 J & J Remicade (infliximab) Drug Product Portfolio
6.1.5 J & J Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Remicade (infliximab) Drug Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Celltrion Healthcare
6.3.1 Celltrion Healthcare Corporation Information
6.3.2 Celltrion Healthcare Description and Business Overview
6.3.3 Celltrion Healthcare Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Celltrion Healthcare Remicade (infliximab) Drug Product Portfolio
6.3.5 Celltrion Healthcare Recent Developments/Updates
6.4 Epirus Biopharmaceuticals
6.4.1 Epirus Biopharmaceuticals Corporation Information
6.4.2 Epirus Biopharmaceuticals Description and Business Overview
6.4.3 Epirus Biopharmaceuticals Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Epirus Biopharmaceuticals Remicade (infliximab) Drug Product Portfolio
6.4.5 Epirus Biopharmaceuticals Recent Developments/Updates
6.5 Samsung Bioepsis
6.5.1 Samsung Bioepsis Corporation Information
6.5.2 Samsung Bioepsis Description and Business Overview
6.5.3 Samsung Bioepsis Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Samsung Bioepsis Remicade (infliximab) Drug Product Portfolio
6.5.5 Samsung Bioepsis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Remicade (infliximab) Drug Industry Chain Analysis
7.2 Remicade (infliximab) Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Remicade (infliximab) Drug Production Mode & Process
7.4 Remicade (infliximab) Drug Sales and Marketing
7.4.1 Remicade (infliximab) Drug Sales Channels
7.4.2 Remicade (infliximab) Drug Distributors
7.5 Remicade (infliximab) Drug Customers
8 Remicade (infliximab) Drug Market Dynamics
8.1 Remicade (infliximab) Drug Industry Trends
8.2 Remicade (infliximab) Drug Market Drivers
8.3 Remicade (infliximab) Drug Market Challenges
8.4 Remicade (infliximab) Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
